TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Relative heart volume receiving 50 Gy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: %APE (atom percent enrichment)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of appearance (Ra) of unlabeled cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: blood cells populations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Indirect and Direct Costs of Treatment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Disease outcome
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of Participants Confirmed as Improvement Responders
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Tear film imager measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Repeatability of Tear film imager measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical measurements of DES compared to TFI measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Nights With Nightmares
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Clinician Administered PTSD Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Past Week Nightmare Frequency
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change in Horizontal Ridge Width
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Volumetric Assessment of Ridge Dimension
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Beck Depression Inventory (BDI-2) Total Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Self Care of Heart Failure Index (SCHFI) Maintenance Subscale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Variations of velocities of middle cerebral artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Variations of pulsatility index of middle cerebral artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Variations of resistance index of middle cerebral artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Moderate diarrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in total 25(OH)D
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Feasibility of smoking cessation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: kel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Negative Polymerase Chain Reaction (PCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage changes in bone mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Diagnostic accuracy of GC/FT-ICR MS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic accuracy of canine scent detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Endoscopic Improvement/Histologic Healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Level of Fecal Calprotectin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Disease Activity Score at Crohn's Disease Endpoint
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spinal cord perfusion pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With AntiCancer Drugs-Related Cardiac Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Blind pulling error
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inflammasome activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Steroid receptor phosphorylation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Agatston score in coronary arteries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Agatston score in aortic valve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Circulating a-Klotho
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TNF-alfa levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: corneal endothelial cell polymorphism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: corneal endothelial cell polymegathism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change on the Modified Roland-Morris Disability Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Treatment discontinuation Rate
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of patients cured
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FDG uptake by muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage Change in Seizures Frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Serum HI Antibody Titers Against the Influenza A Virus Strain Subtype H9N2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Seroconverted Subjects Against Influenza A Subtype H9N2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Seroprotected Subjects Against H9N2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Habitual physical activity level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time spent in sedentary behaviour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in ME/CFS symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Depression scale (PHQ9-A)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: PET scan response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maintenance of PASI 90 Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: change in glucose disposal rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Quality score of pediatric practices
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of Participants Experiencing Adverse Events Defined as Dose-Limiting Toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Length for Age
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Prevention of COVID-19 infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Whole Brain Relative Regional Cerebral Metabolic Rate of Glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: PDL-1 expression on circulating tumor cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Impact of High-dose 3F8/GM-CSF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sleep architecture (distribution of sleep stages)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving Minimal Improvement in IMACS TIS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: post-operative opiate consumption
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Pain amplitude reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Closure of fistulas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Transfusion Related Events
Endpoint domain: Adverse events/effects
Primary endpoint: Strength, Arm Curl Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Strength, Chair Stand Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Quantitative Insulin Sensitivity Check Index (QUICKI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Unified Parkinson's Disease Rating Scale (Part III)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) Pain Intensity Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction of stress parameters
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in T Cell Subpopulations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in cardiovascular fitness (total seconds)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline to Month 18 in Cognitive Subscale of the Alzheimer´s Disease Assessment Scale (ADAS-Cog)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change From Baseline to Month 18 in Alzheimer´s Disease Cooperative Study (ADCS)-Activities of Daily Living (ADL) Inventory
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Incremental cost effectiveness ratio (ICER)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of patients with SpO2 < 80%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in 24-hour Mean Systolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: serum free testosterone concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Combined risk of death or rehospitalization within 30 days
Endpoint domain: Mortality/survival
Primary endpoint: health self efficacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: goal adherence
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Acetabular index (AI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence assessment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Voluntary maximum contraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of the Advanced CustomVue™ iLASIK procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Predictability of the Advanced CustomVue™ iLASIK procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of the Advanced CustomVue™ iLASIK procedure
Endpoint domain: Adverse events/effects
Primary endpoint: Bone density measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Measures of Reaction Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Measures of Mental Performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Measures of Cognitive Fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Cheeks appearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the thickness of the echolucent band (ELB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression-free survival (PFS) at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive Predictive Value of Earliest Available Platelet Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Patency rates of vein grafts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Trough Observed Plasma Concentration (Ctrough)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve (AUC[TAU])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rate of BCC lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Bone Mineral Density (BMD) at Lumbar Spine (L2-L4)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Postpartum hemorrhage (PPH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Rate of Cancellation
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Rate of Missed Appointments
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Total Use of Opioid Rescue Analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression Free Survival (PFS) rate at 6 months
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Participants Who Reported 1 or More Adverse Event (AE) - Healthy Participants
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Who Report 1 or More Adverse Event (AE) - Hypertensive Participants
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Who Were Discontinued From the Study Due to an AE - Hypertensive Participants
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Predefined Cardiovascular Treatment-Emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Subjective assessment of Haemostatic efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incremental recovery of FVIII
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Half-life of FVIII
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With at Least 1 Treatment-Emergent Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With at Least 1 Treatment-Emergent Serious Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Number of pain pills taken
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Chemoprevention uptake rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of patients receiving convalescent plasma transfusions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Aortic target to background ratio (Aortic TBR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Participants Achieving CR or PR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Investigator five point global aesthetic improvement score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Cutometer Measured Skin Elasticity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Hydrometer measured Transepidermal Water Loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Procalcitonin Kinetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Physician-determined procedure success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom from local tumor progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in stage of adoption of health behaviors
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Referral for additional screening and follow up
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Safety Evaluation of Risperidone
Endpoint domain: Adverse events/effects
Primary endpoint: Change in VSC concentration in mouth air
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of the size (area) of lithiasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of generated fragments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hardness of lithiasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving Disease Modifying Response (DMR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Iron concentration measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients With Modified Diagnosis Probability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HIV testing frequency
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Seizure reduction after DBS surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Seizure reduction after VNS surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Volume of white matter changes (WMCs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Drop in PAS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone Ingrowth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in health-related quality of life (QOL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Frequency of adverse events of INBRX-106
Endpoint domain: Adverse events/effects
Primary endpoint: Severity of adverse events of INBRX-106
Endpoint domain: Adverse events/effects
Primary endpoint: Antitumor activity of INBRX-106
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: % of patients with positive serological tests for covid-19
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Participation to colorectal cancer screening
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Foot volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eating habits
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Alleviation of Influenza Illness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in the Patient Symptoms Questionnaire (PSQ) Derived Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: grade II-IV acute GVHD
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Eye Dryness Score (EDS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completion of 80% sessions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Degree of deposition of ET-1 in skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Decrease pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration-time curve (AUC0-inf) of total dabigatran
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum measured concentration (Cmax) of total dabigatran
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Narcotics consumption
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Utian Quality of Life (UQOL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Occurrence of HPV-16 and HPV-18
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: number of attempts with Glidescope laryngoscopy for proficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in expression of genes protecting skin cells from UVB damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: parietal ultrasound
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of local relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Changes of left ventricular systolic function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes of apnea-hypopnea index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Changes of global longitudinal strain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes of right ventricular systolic function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Complications during surgery and post-operative follow-up
Endpoint domain: Adverse events/effects
Primary endpoint: Average Monitoring Frequency
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Mean bilateral sunburn comparison
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: repair of double strand break in DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes